The Department of Industry, Innovation and Science has released a Regulation Impact Statement (RIS) for community consultation on Country of Origin labelling for Australian complementary medicines.
Developed by the Council of Australian Government (COAG), the RIS addresses the situation in which some complementary medicines made in Australia come under regulation by the Therapeutic Goods Administration (TGA) and others under the Australian Consumer Law and the requirements for using the Australian Made, Australian Grown (AMAG) logo.
“The Regulation Impact Statement explores options which reflect quality assurance and product safety balanced with consumer protections and perceptions,” the Department said.
It said this included maintenance of the status quo or self-regulation by industry.
It said that another possibility was the changing of the Australian Consumer Law to allow Australian manufactured complementary medicines made substantially or entirely from imported ingredients to have access to the Australian Made, Australian Grown logo.
“The Consultation Regulation Impact Statement has been assessed by the Office of Best Practice Regulation as compliant with the Council of Australian Government’s Best Practice Regulation requirements,” the Department said.
Comments on the 56-page Consultation RIS are invited by 30 October and it can be accessed at this PS News link.
